Silo Pharma (SILO) versus The Competition Financial Analysis

Volatility and Risk

Silo Pharma has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Silo Pharma’s peers have a beta of 3.84, meaning that their average share price is 284% more volatile than the S&P 500.

Institutional & Insider Ownership

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 4.4% of Silo Pharma shares are owned by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Silo Pharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-5,255.05%	-61.38%	-47.49%
Silo Pharma Competitors	-3,399.87%	-235.11%	-32.77%

Earnings and Valuation

This table compares Silo Pharma and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Silo Pharma	$72,102.00	-$3.70 million	-0.93
Silo Pharma Competitors	$9.90 billion	$136.37 million	-5.95

Silo Pharma’s peers have higher revenue and earnings than Silo Pharma. Silo Pharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Silo Pharma peers beat Silo Pharma on 7 of the 9 factors compared.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.